Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in HR+ HER2-ve Breast ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

Genentech Executive Levi Garraway, MD, PhD, called the approval "an important new first-line option for people living with HR+ breast cancer with a PIK3CA mutation" in a company press release.

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

A mutation in the gene known as PIK3CA causes cells to divide and replicate uncontrollably, leading to the development of ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

HR+/HER2- is the most common subtype, accounting for approximately 70% of all breast cancers, and more than 40% of these are diagnosed in stage II or III 8-10.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Breast cancer is the most commonly diagnosed cancer in Europe. HR+/HER2- is the most common subtype, accounting for approximately 70% of all breast cancers, and more than 40% of these are diagnosed in ...